The GSK oncology products it has sold on to Novartis were ... particularly if GSK is not looking to reinvest in oncology. However a major outlay looks unlikely, at least in connection to the ...
GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and ... Sales of shingles vaccine Shingrix - the main driver for GSK's sales growth of late - fell 9% in the year on pandemic ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback